Purchase this article with an account.
Yicheng Chen, Bradley T Smith; Exogenous Testosterone Use and Central Serous Chorioretinopathy. Invest. Ophthalmol. Vis. Sci. 2016;57(12):2036.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Central serous chorioretinopathy (CSCR) has been associated with psychosocial stress, systemic corticosteroid use, type A personality, pregnancy and endogenous Cushing's syndrome. Case reports in the literature suggest a possible link between CSCR and testosterone. We performed a retrospective chart review of patients with CSCR between 2013 and 2015 to examine the prevalence of testosterone use among CSCR patients and the clinical characteristics of CSCR in the setting of exogenous testosterone use.
Patients seen between 2012 and 2015 who have a diagnosis of CSCR were identified through the electronic medical record of a large retina practice. The electronic records of all patients with a history of exogenous testosterone use and a diagnosis of CSCR were reviewed.
480 patients with a diagnosis of CSCR were identified, of which 7 patients had a history of exogenous testosterone use (1.46%). 0/7 patients reported any other steroid use. The age of the patients ranged from 36-55 (mean 46.57) and all were male. Only the right eye was involved in all 7 patients. Testosterone was discontinued in only 1/7 patients. 6/7 patients had a visual acuity of 20/40 or better at last follow-up (range 20/20 to 4/200). 4/7 (57%) had resolution of subretinal fluid at their last visit.
CSCR patients with a history of exogenous testosterone use accounted for a small percentage of all CSCR patients in the study (1.46%). The majority of patients in this study recovered 20/40 or better vision and 57% had resolution of subretinal fluid on OCT, suggesting a generally favorable prognosis for CSCR in the setting of testosterone supplementation, even without discontinuation of testosterone. Future studies on a larger scale are needed to elucidate the role, if any, that testosterone plays in central serous chorioretinopathy.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.
Table 1. Patient Clinical Characteristics. *Patient 2 developed subsequent CNVM in the right eye.
This PDF is available to Subscribers Only